Cancers (Jul 2022)
Two Decades of Brain Tumour Imaging with O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience
- Alexander Heinzel,
- Daniela Dedic,
- Norbert Galldiks,
- Philipp Lohmann,
- Gabriele Stoffels,
- Christian P. Filss,
- Martin Kocher,
- Filippo Migliorini,
- Kim N. H. Dillen,
- Stefanie Geisler,
- Carina Stegmayr,
- Antje Willuweit,
- Michael Sabel,
- Marion Rapp,
- Michael J. Eble,
- Marc Piroth,
- Hans Clusmann,
- Daniel Delev,
- Elena K. Bauer,
- Garry Ceccon,
- Veronika Dunkl,
- Jurij Rosen,
- Caroline Tscherpel,
- Jan-Michael Werner,
- Maximilian I. Ruge,
- Roland Goldbrunner,
- Jürgen Hampl,
- Carolin Weiss Lucas,
- Ulrich Herrlinger,
- Gabriele D. Maurer,
- Joachim P. Steinbach,
- Jörg Mauler,
- Wieland A. Worthoff,
- Bernd N. Neumaier,
- Christoph Lerche,
- Gereon R. Fink,
- Nadim Jon Shah,
- Felix M. Mottaghy,
- Karl-Josef Langen
Affiliations
- Alexander Heinzel
- Department of Nuclear Medicine, RWTH University Hospital, D-52074 Aachen, Germany
- Daniela Dedic
- Department of Nuclear Medicine, RWTH University Hospital, D-52074 Aachen, Germany
- Norbert Galldiks
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Philipp Lohmann
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Gabriele Stoffels
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Christian P. Filss
- Department of Nuclear Medicine, RWTH University Hospital, D-52074 Aachen, Germany
- Martin Kocher
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Filippo Migliorini
- Department of Orthopedics, Trauma, and Reconstructive Surgery, RWTH University Hospital, D-52074 Aachen, Germany
- Kim N. H. Dillen
- Department of Palliative Medicine, University Hospital Cologne, D-50937 Cologne, Germany
- Stefanie Geisler
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Carina Stegmayr
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Antje Willuweit
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Michael Sabel
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Marion Rapp
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Michael J. Eble
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Marc Piroth
- Department of Radiation Oncology, Helios University Hospital Wuppertal, Witten/Herdecke University, D-42283 Wuppertal, Germany
- Hans Clusmann
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Daniel Delev
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Elena K. Bauer
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Garry Ceccon
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Veronika Dunkl
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Jurij Rosen
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Caroline Tscherpel
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Jan-Michael Werner
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Maximilian I. Ruge
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Roland Goldbrunner
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Jürgen Hampl
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Carolin Weiss Lucas
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Ulrich Herrlinger
- Center of Integrated Oncology (CIO), University of Aachen, D-52074 Aachen, D-53127 Bonn, D-50937 Cologne, D-40225 Düsseldorf, Germany
- Gabriele D. Maurer
- Dr. Senckenberg Institute of Neurooncology, University Cancer Center Frankfurt (UCT), Goethe University Hospital, D-60528 Frankfurt am Main, Germany
- Joachim P. Steinbach
- Dr. Senckenberg Institute of Neurooncology, University Cancer Center Frankfurt (UCT), Goethe University Hospital, D-60528 Frankfurt am Main, Germany
- Jörg Mauler
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Wieland A. Worthoff
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Bernd N. Neumaier
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Christoph Lerche
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Gereon R. Fink
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Nadim Jon Shah
- Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, D-52425 Jülich, Germany
- Felix M. Mottaghy
- Department of Nuclear Medicine, RWTH University Hospital, D-52074 Aachen, Germany
- Karl-Josef Langen
- Department of Nuclear Medicine, RWTH University Hospital, D-52074 Aachen, Germany
- DOI
- https://doi.org/10.3390/cancers14143336
- Journal volume & issue
-
Vol. 14,
no. 14
p. 3336
Abstract
O-(2-[18F]fluoroethyl)-L-tyrosine (FET) is a widely used amino acid tracer for positron emission tomography (PET) imaging of brain tumours. This retrospective study and survey aimed to analyse our extensive database regarding the development of FET PET investigations, indications, and the referring physicians’ rating concerning the role of FET PET in the clinical decision-making process. Between 2006 and 2019, we performed 6534 FET PET scans on 3928 different patients against a backdrop of growing demand for FET PET. In 2019, indications for the use of FET PET were as follows: suspected recurrent glioma (46%), unclear brain lesions (20%), treatment monitoring (19%), and suspected recurrent brain metastasis (13%). The referring physicians were neurosurgeons (60%), neurologists (19%), radiation oncologists (11%), general oncologists (3%), and other physicians (7%). Most patients travelled 50 to 75 km, but 9% travelled more than 200 km. The role of FET PET in decision-making in clinical practice was evaluated by a questionnaire consisting of 30 questions, which was filled out by 23 referring physicians with long experience in FET PET. Fifty to seventy per cent rated FET PET as being important for different aspects of the assessment of newly diagnosed gliomas, including differential diagnosis, delineation of tumour extent for biopsy guidance, and treatment planning such as surgery or radiotherapy, 95% for the diagnosis of recurrent glioma, and 68% for the diagnosis of recurrent brain metastases. Approximately 50% of the referring physicians rated FET PET as necessary for treatment monitoring in patients with glioma or brain metastases. All referring physicians stated that the availability of FET PET is essential and that it should be approved for routine use. Although the present analysis is limited by the fact that only physicians who frequently referred patients for FET PET participated in the survey, the results confirm the high relevance of FET PET in the clinical diagnosis of brain tumours and support the need for its approval for routine use.
Keywords
- brain tumour diagnosis
- positron emission tomography
- L-tyrosine (FET)%22%2C%22default_operator%22%3A%22AND%22%7D%7D%7D"> O-(2-[<sup>18</sup>F]fluoroethyl)-<span style="font-variant: small-caps">L</span>-tyrosine (FET)
- glioma
- brain metastasis
- amino acid PET